Skip to main content

Interpretable Prediction of Lymphopenia Following Neoadjuvant Chemoradiotherapy for rectal Cancer: An Analysis of the ARISTOTLE randomized phase 3 Trial

In brief

A model explained 65% of lymphocyte-count variation during rectal cancer treatment

In 498 patients receiving chemoradiotherapy for locally advanced rectal cancer, a model explained 65% of weekly lymphocyte-count variation in an independent test set. Radiation exposure to circulating blood was the strongest predictor, and a 0.75 relative-change cutoff separated groups with different progression-free survival; whether using these predictions to guide treatment improves outcomes remains unknown.

Journal
Clinical oncology (Royal College of Radiologists (Great Britain)) (Q1)
Published
14 October 2026
Study design
Randomized controlled trial
Evidence level
Level 1, High (CEBM 1b)
Authors
Y Zhang, D Brand, S Hindocha, A Appelt, N West, Z Shen, et al.
PMID
43019770
DOI
10.1016/j.clon.2026.104351

Why clinicians should know about it

Abstract

AIMS: This study aimed to develop a mechanistic model explaining the development of lymphopenia during neoadjuvant chemoradiotherapy and investigate how changes in lymphocyte counts relate to survival in patients with locally advanced rectal cancer. MATERIALS AND METHODS: We retrospectively analyzed 2485 lymphocyte count measurements from 498 patients enrolled in the phase 3 trial ARISTOTLE across 73 centers. We developed a parametric exponential model to predict weekly lymphocyte counts. Segmentations of bone and blood vessel-rich organs were generated on computed tomography using an artificial intelligence segmentation tool, TotalSegmentator, for dose metric calculations. Covariates included in the prediction were age, gender, pretreatment lymphocyte counts, cumulative radiotherapy doses to bones, estimated blood dose from a dynamic blood flow model, and cumulative chemotherapy doses. Bootstrap Cox regression identified the cutoff for relative lymphocyte change from pretreatment to nadir (ΔL) linked to progression-free survival (PFS). RESULTS: The lymphocyte prediction model explained 65% of the variation in weekly lymphocyte counts in the independent test dataset (r2 = 0.65, 95% CI 0.56-0.72), with a mean absolute prediction error of 0.24 (95% CI 0.21-0.29). The strongest predictor of lymphocyte counts was the radiation dose received by 95% of the estimated circulating blood volume, followed by treatment with capecitabine and irinotecan. The optimal cutoff threshold of ΔL was 0.75 ± 0.03. The categorized ΔL was significantly associated with PFS in multivariate Cox regression (hazard ratio: 1.24 [95% CI: 1.07-1.43], P < .005). CONCLUSION: This study identifies key treatment-related factors that contribute to lymphocyte depletion and the impact of categorized ΔL on PFS in locally advanced rectal cancer.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.